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Although several dosage adjustment regimens have been proposed, there is little quantitative information to
guide the initiation of ceftazidime therapy in patients who are receiving continuous renal replacement therapy.
To determine the clearance of ceftazidime by continuous venovenous hemofiltration (CVVH) and continuous
venovenous hemodialysis (CVVHD), we performed controlled clearance studies with stable hemodialysis patients with three hemofilters: a 0.6-m 2 acrylonitrile copolymer (AN69; Hospal) filter, a 2.1-m 2 polymethylmethacrylate filter (PMMA; Toray) filter and a 0.65-m 2 polysulfone (PS; Fresenius) filter. Subjects received
1,000 mg of ceftazidime intravenously prior to the start of a clearance study. The concentration of ceftazidime
in multiple plasma and dialysate or ultrafiltrate samples was determined by high-performance liquid chromatography. The diffusional clearances (CIdiffusion) and sieving coefficients of ceftazidime were compared by a
mixed-model repeated-measures analysis of variance with filter and blood, dialysate inflow, or ultrafiltration
rate as the main effect and the patient as a random effect. The fraction of ceftazidime bound to plasma proteins
was 17% ⴞ 7% (range, 10 to 25%). The clearances of ceftazidime, urea, and creatinine by CVVHD were
essentially constant at blood flow rates of 75 to 250 ml/min for all three filters. Significant linear relationships
(P < 0.0001) were observed between CIdiffusion of ceftazidime and clearance of urea for all three filters: AN69
(slope ⴝ 0.83), PMMA (slope ⴝ 0.89), and PS (slope ⴝ 1.03). Ceftazidime clearance was membrane independent during CVVH and CVVHD. CVVH and CVVHD can significantly augment the clearance of ceftazidime.
Dosing strategies for initiation of ceftazidime therapy in patients receiving CVVH and CVVHD are proposed.
body weight (range, 0.22 to 0.27 liter/kg) (2). The fraction of
ceftazidime excreted unchanged by the kidney is ⬃90% in
subjects with normal renal function. Thus, the half-life of ceftazidime increases significantly in patients with renal insufficiency (2). The reported clearance of ceftazidime during
CVVH, CVVHD, or CVVHDF or their arterial derivatives
ranges from 4.2 to 24.0 ml/min (3, 6, 12, 13, 27). The methods
utilized to determine the clearance of ceftazidime, however,
were often not provided or consisted of multiple assumptions
(e.g., normal degree of protein binding and consistency of
blood, dialysate, and ultrafiltrate flow rates). Unfortunately,
many of these studies had limited statistical power due to small
sample size (n ⫽ 2 to 5), poorly defined continuous renal
replacement therapy (CRRT) conditions (i.e., dialysate, ultrafiltration, and blood flow rates; hemofilter type; length of therapy), or the lack of documentation of adequacy of removal of
a reference solute (i.e., urea or creatinine). This study was,
therefore, designed to rigorously evaluate the extracorporeal
clearance of the prototype middle molecule, ceftazidime, by
CVVH and CVVHD in stable end-stage renal disease (ESRD)
patients in order to assess the influence of critical procedural
variables on drug clearance. This study was performed with
ESRD patients, since it is difficult if not impossible to conduct
rigorous structured studies that may require modification of
the prescribed therapeutic CVVH or CVVHD regimen for
critically ill patients.

Continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) are frequently utilized to manage hemodynamically unstable patients who are
volume overloaded or have acute renal failure (4, 13, 20).
Continuous venovenous hemodiafiltration (CVVHDF), which
employs diffusion as well as convection, may also be utilized,
particularly for hypercatabolic patients (23). Drug clearance by
CVVH is dependent on the ultrafiltration rate and the sieving
coefficient (SC) for the particular solute or drug of interest (3,
16). The clearance of medications by CVVHD is predominantly dependent on the dialysate flow rate, since solute and/or
drug removal is primarily diffusive (16). In addition to the
ultrafiltration rate and dialysate flow rate, the removal of solutes or drugs by CVVH, CVVHD, or CVVHDF may be dependent on the type of hemofilter utilized (24). The clearance
of some small and large molecules has been reported to vary
markedly between hemofilters, even when all other procedural
variables are held constant (14, 17, 19). Finally, the use of
pump-driven systems (i.e., CVVH and CVVHD) may enhance
drug clearance due to the consistency of blood flow compared
to continuous arteriovenous hemofiltration and continuous arteriovenous hemodialysis.
Although low-to-intermediate-molecular-mass (500 to 1,000
Da) drugs are removed with cellulosic dialyzers, their removal
may be enhanced when synthetic filters are utilized (1, 25).
Ceftazidime is a prototypical low-to-intermediate-molecularmass drug (547 Da). Ceftazidime is approximately 17% protein
bound and has a volume of distribution of about 0.25 liter/kg of

MATERIALS AND METHODS
Eight patients with ESRD who were receiving conventional maintenance hemodialysis participated in this study after granting written informed consent. The
Biomedical Institutional Review Board and the General Clinical Research Center Committee of the University of Pittsburgh approved the study and consent
document. The clearance of ceftazidime by CVVH and CVVHD was determined
during a 12-h procedure (see details below) for each of the three hollow fiber

* Corresponding author. Mailing address: University of Pittsburgh,
School of Pharmacy, 724 Salk Hall, Pittsburgh, PA 15261. Phone: (412)
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TABLE 1. Clinical characteristics of the patients
who participated in this studya
Filter

Age (yr)

Wt (kg)

Race (no. AfricanAmerican/no.
Caucasian)

Gender
(no. male/
no. female)

AN69
PMMA
PS

39.2 (9.4)
41.8 (14.5)
50.2 (7.9)

77.4 (18.8)
80.0 (23.4)
69.4 (11.7)

4/1
4/1
4/1

1/4
2/3
2/3

a

Age and weight data are means with standard deviations in parentheses.

dosage regimens were, therefore, derived by the Tozer method (21). In this
scenario, after the administration of a normal loading dose, the projected maintenance dose was reduced in proportion to the patient’s degree of renal insufficiency and administered at a practical clinical value of every 12 h to maximize
the time above the MIC. An intravenous dose of 1 g every 8 h was utilized as the
“normal” maintenance dose for ceftazidime. This should result in the maintenance of unbound serum drug concentrations above the MIC at which 90% of
susceptible organisms (4 mg/liter) are inhibited (MIC90) (7, 11) for over 80% of
the dosing interval.
Statistics. The demographic characteristics of the three filter groups for each
drug were compared by analysis of variance (ANOVA). The total and unbound
clearance of ceftazidime, urea, and creatinine by the three filters during CVVH
and CVVHD were compared by a mixed-model repeated-measures ANOVA
with filter and flow rate as the main effects and with the patient as a random
effect. We determined that a sample size of five subjects per group would allow
for the detection of an effect size of 1.0 for within-filter comparisons and 2.0 for
between-filter comparisons. This translates into the ability to detect a 25%
difference in ceftriaxone clearance within filter and a 75% difference in clearance
between filters with 80% power at the 0.05 level of significance. Linear regression
analysis was performed to determine the relationship between dialysate, blood,
or ultrafiltration rate and CVVHD and CVVH clearance of urea, creatinine, and
ceftazidime, respectively. Regression lines were compared by using t tests for
common slopes. Results were calculated as means ⫾ standard deviations. Computations were performed with version 6.12 of Statistical Analysis Software (SAS
Institute, Cary, N.C.), and P ⬍ 0.05 was considered to be statistically significant.

RESULTS
The patients in each of the three hemofilter groups were
similar with regard to age, gender, race, weight, and pertinent
laboratory measurements (Table 1). The residual renal function of the patients was not characterized, since the aim of the
study was to ascertain the extracorporeal clearance of ceftazidime. None of the patients experienced any adverse events
while participating in this study.
CVVH clearance. Ceftazidime was minimally protein bound
in these ESRD subjects (free fraction ranged from 0.75 to
0.90). No significant differences in fraction unbound to plasma
proteins (fup) were noted between the three groups of patients
(AN69, fup ⫽ 0.80 ⫾ 0.04; PS, fup ⫽ 0.85 ⫾ 0.03; PMMA,
fup ⫽ 0.83 ⫾ 0.06). The SCs of ceftazidime for the PMMA
(0.80 ⫾ 0.19), AN69 (0.97 ⫾ 0.11), and PS (0.97 ⫾ 0.13) filters
were not significantly different (P ⫽ 0.279) from each other or
from the fup of their respective group. The convective clearances of urea and ceftazidime at ultrafiltration rates of 500 and
1,000 ml/h for the AN69, PS, and PMMA filters are depicted in
Fig. 1. The convective clearance of ceftazidime by each filter
was significantly increased at the higher ultrafiltration rate
(P ⫽ 0.0001).
CVVHD clearance versus dialysate inflow rate. Urea and
creatinine clearance increased linearly with dialysate inflow
rates for all three filters (Table 2). The regression lines for urea
clearance for the filters when plotted against dialysate inflow
rate had similar slopes of 0.84 (r 2 ⫽ 0.980, P ⫽ 0.0001), 0.82
(r 2 ⫽ 0.933, P ⫽ 0.0001), and 0.83 (r 2 ⫽ 0.937, P ⫽ 0.0001) for
the AN69, PS, and PMMA filters, respectively (P ⬎ 0.05). The
regression analysis for creatinine clearance yielded similar results.
The clearance of total ceftazidime by the PS filter was sim-
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hemofilters evaluated. These included a 0.6-m 2 acrylonitrile and sodium methallyl sulfonate copolymer (AN69) hemofilter (Hospal Multiflow 60; CGH Medical), a 2.1-m 2 polymethylmethacrylate (PMMA) hemofilter (Filtryzer B1-2.1U;
Toray Industries), and a 0.65-m 2 polysulfone (PS) hemofilter (Fresenius F40;
Fresenius AG). A total of five clearance procedures were performed with each
hemofilter. Each 12-h CRRT procedure was performed in addition to the patient’s regularly scheduled hemodialysis treatments.
CRRT procedure. Venous access was obtained by cannulation of the patient’s
hemodialysis arteriovenous fistula or polytetrafluoroethylene graft. The inlet and
outlet ports of the filter were connected to the patient via CVVH tubing. Blood
flow rate was regulated by the use of a roller pump (Sarns, Ann Arbor, Mich.).
An air detector with an automatic pump shut-off was located distal to the drip
chamber on the venous return. Dialysate was pumped countercurrent to blood by
utilizing linear peristaltic pumps which controlled both the inflow and outflow
rates (Flowgard 6300; Baxter Healthcare Corp., Deerfield, Ill.). These pumps
allowed a maximal delivery rate of 1,999 ml/min. Hemodiafiltration fluid (Baxter
Healthcare Corp.) was used as a dialysate. No replacement fluids were administered during the CVVH or CVVHD clearance studies. Heparin was infused
through a prehemofilter port with initial dosages corresponding to the rate
prescribed during the patients’ conventional hemodialysis session. The heparin
infusion rate was monitored during the procedure and titrated to achieve an
activated clotting time of between 120 and 180 s.
Clearance studies. The patients received a 1,000-mg intravenous dose of
ceftazidime administered as a 1-h infusion. The minimum time between the end
of the infusion and the commencement of the clearance study of 1 h ensured that
the clearance evaluations were performed during the postdistributive phase.
Study participants were admitted to the Clinical Research Center outpatient
facility the morning of the clearance study. All clearance studies were performed
under controlled dialysate, blood, and ultrafiltrate conditions as described below.
The effect of dialysate inflow rate on clearance was determined by increasing
the dialysate flow rate incrementally at hourly intervals from 8.3 to 16.7, 25, and
33.3 ml/min while nominal blood and ultrafiltration flow rates were held constant
at 100 and 0 ml/min, respectively. The effect of blood flow rate on clearance was
determined by increasing the blood flow rate hourly from 75 to 125, 150, and 250
ml/min while the dialysate and ultrafiltration flow rates were held constant at 33.3
and 0 ml/min, respectively. The SC and CVVH clearance were assessed at
nominal ultrafiltrate flow rates of 500 and 1,000 ml/h while maintaining blood
and dialysate flow rates of 100 and 0 ml/min, respectively. CVVH clearances of
ceftazidime, urea, and creatinine at the two ultrafiltration rates were determined
during two 15-min periods, after an initial 15-min equilibration period. Each
CVVHD clearance study period consisted of an initial 20-min equilibration
period and two 20-min clearance determinations. Blood samples were collected
at the midpoint of each dialysate or ultrafiltrate collection period.
Analytical. The concentrations of urea and creatinine in the plasma and
dialysate or ultrafiltrate specimens were determined with an Ektachem 700 XRC
autoanalyzer (Eastman Kodak, Rochester, N.Y.). The total (bound and unbound) concentrations of ceftazidime in plasma and dialysate were determined
by reverse-phase high-performance liquid chromatography (HPLC) with UV
detection. Plasma proteins were precipitated with perchloric acid to release drug
from its binding sites, and an aliquot of the supernatant was injected into the
HPLC system. Separation was achieved with a Microsorb MV C18 column (100
by 4.6 mm; 3 m) and a mobile phase consisting of 18% methanol and phosphate
buffer. The assay was linear over the concentration range of 5.0 to 200 g/ml in
plasma and dialysate. The inter- and intraday coefficients of variation were less
than 10% in plasma ultrafiltrate and dialysate.
The fraction of ceftazidime bound to plasma proteins was determined by
filtration. Plasma (0.5 ml) was incubated at 37°C for 1 h and then placed in a
Centrifree filtration device (molecular weight cutoff, 30,000; Amicon, Beverly,
Mass.) and centrifuged for 30 min in a fixed-angle centrifuge. The protein-free
filtrate was collected and then analyzed as described above. The concentration of
drug in the filtrate represents the portion of the plasma concentration that is
unbound.
Pharmacokinetic analysis. The clearance of urea, creatinine, and ceftazidime
(total and unbound) was calculated during each CVVHD period as CL ⫽
(QDO ⫻ CDO)/CPmid, where CL is solute clearance during CVVHD, QDO is
hemofilter outflow rate, CDO is concentration of solute in the hemofilter outflow,
and CPmid is concentration of solute in the plasma at the midpoint of the
collection period.
The SCs of ceftazidime (total and unbound) were calculated during each
CVVH period as SC ⫽ CUF/CP, where ultrafiltrate concentration (CUF) and
plasma drug concentration (CP) were determined from simultaneously collected
specimens. The clearance of urea, creatinine, and ceftazidime was calculated
during the four CVVH observation periods as CLCVVH ⫽ (CUF 䡠 QUF) /CPmid,
where CUF is the concentration of solute in the ultrafiltrate and QUF is the
ultrafiltrate flow rate.
Dosing regimens for ceftazidime were calculated from the observed CVVH
and CVVHD clearance data by assuming a nonrenal clearance of 10.6 ml/min for
total ceftazidime (18). The residual renal clearances of total ceftazidime associated with creatinine clearances (CLcr) of 0 to 120 ml/min were assumed to be
1.15 䡠 CLcr (18). The best predictor of bacterial killing and, thereby, clinical
efficacy of cephalosporins, is the time within a dosage interval that plasma drug
concentrations exceed the MIC for the infecting organism (5, 26). Projected
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ilar to that by the PMMA filter, but exceeded the values observed with the AN69 filter at a dialysate inflow rate of 25.0
and 33.3 ml/min, (P ⫽ 0.027 and 0.0083, respectively) (Table
2). Ceftazidime total and unbound clearance was significantly
correlated with the dialysate inflow rate for all three filters
(Fig. 2). The slopes of the relationships between dialysate inflow rate and unbound and total ceftazidime with the PMMA,
AN69, and PS filters were similar.
Regression analysis revealed significant linear relationships
between total ceftazidime clearance and urea clearance for all
three filters: AN69 (slope ⫽ 0.83, r 2 ⫽ 0.956, P ⫽ 0.0001), PS
(slope ⫽ 1.03, r 2 ⫽ 0.951, P ⫽ 0.0001), and PMMA (slope ⫽
0.89, r 2 ⫽ 0.933, P ⫽ 0.0001) (Fig. 3). The slopes were not
significantly different. The relationships between clearance of
unbound ceftazidime and urea clearance were also similar.
Although the slopes were higher for all three filters, they were

not significantly different from the total ceftazidime clearance
versus urea clearance relationships: AN69 (slope ⫽ 1.04, r 2 ⫽
0.968, P ⫽ 0.0001), PS (slope ⫽ 1.21, r 2 ⫽ 0.943, P ⫽ 0.0001),
and PMMA (slope ⫽ 1.08, r 2 ⫽ 0.919, P ⫽ 0.0001).
CVVHD clearance versus blood flow. Ceftazidime, urea, and
creatinine clearances were also measured at a constant dialysate inflow rate of 33.3 ml/min, while the blood flow rate was
increased from 75 to 250 ml/min. The clearances of urea and
TABLE 2. Ceftazidime, creatinine, and urea clearance in relation
to dialysate inflow for AN69, PS, and PMMA filtersa
Type of clearanceb

8.3

16.7

25.0

33.3

8.4 (0.6)
8.6 (1.3)
7.3 (1.7)

13.5 (1.1)
16.6 (2.4)
14.5 (4.5)

18.3 (1.9)
23.2 (2.9)#
20.1 (4.9)

21.6 (2.2)
27.5 (3.7)##
24.2 (5.2)

10.5 (0.5)
10.1 (1.5)
8.9 (2.4)

16.9 (1.8)
19.5 (2.9)
17.5 (5.7)

22.8 (1.2)
27.3 (3.3)
24.4 (7.0)

26.9 (1.5)
32.4 (4.5)
29.5 (7.9)

Urea
AN69 filter⫹
PS filter⫹⫹
PMMA filter⫹⫹⫹

7.6 (0.6)
6.2 (1.6)
6.7 (1.0)

13.1 (3.0)
14.0 (4.0)
16.1 (5.4)

21.5 (2.6)
20.7 (5.9)
19.8 (6.3)

28.1 (4.2)
26.9 (8.8)
27.5 (6.6)

Creatinine
AN69 filter⫹
PS filter°
PMMA filter°°

6.7 (0.6)
5.6 (1.5)
5.9 (1.0)

11.3 (2.5)
12.7 (3.5)
14.5 (4.8)

18.0 (3.2)
19.2 (5.9)
18.3 (6.6)

22.7 (4.0)
23.3 (7.8)
24.4 (5.5)

Total ceftazidime
AN69 filter
PS filter⫹
PMMA filter⫹
Unbound ceftazidime
AN69 filter⫹
PS filter⫹
PMMA filter⫹

a

Data are means with standard deviations in parentheses.
Within-filter comparisons. ⫹, clearance at dialysate inflow rate ⫽ 33.3 ⬎
25.0 ⬎ 16.7 ⬎ 8.3 (P ⫽ 0.0001); ⫹⫹, clearance at dialysate inflow rate ⫽ 33.3 ⬎
16.7 ⬎ 8.3 and 25 ⬎ 8.3 (P ⫽ 0.0007); ⫹⫹⫹, clearance at dialysate inflow rate ⫽
33.3 ⬎ 25 and 16.7 ⬎ 8.3 (P ⫽ 0.0001); °, clearance at dialysate inflow rate ⫽
33.3 ⬎ 16.7 ⬎ 8.3 and 25 ⬎ 8.3 (P ⫽ 0.0027); °°, clearance at dialysate inflow
rate ⫽ 33.3 and 25 and 16.7 ⬎ 8.3 and 33.3 ⬎ 16.7 (P ⫽ 0.002).
c
Between-filter comparisons. #, ceftazidime clearance by PS ⬎ AN69 (P ⫽
0.027); ##, ceftazidime clearance by PS ⬎ AN69 (P ⫽ 0.0083).
b

FIG. 2. Ceftazidime clearance in relation to dialysate inflow rate for the
AN69 (total, open circles; unbound, solid circles), PS (total, open triangles;
unbound, solid triangles), and PMMA (total, open squares; unbound, solid
squares) filters at a constant blood flow rate of 100 ml/min. Values are means ⫾
standard errors.

Clearance at dialysate inflow rate (ml/min) of c:
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FIG. 1. Convective clearance of ceftazidime at low (LO) and high (HI) ultrafiltration rates. The increment in ultrafiltrate flow rate resulted in a significant increase
in ceftazidime clearance with all three filters (P ⫽ 0.0001). The data are means ⫾ standard deviations.
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creatinine were essentially constant at all blood flow rates for
all three filters. The clearance of ceftazidime with the AN69
filter, however, did increase significantly from 18.7 ml/min at a
blood flow rate of 75 ml/min to 23.9 ml/min at a blood flow rate
of 250 ml/min (P ⫽ 0.031).
Comparison of membranes. The CVVH clearances of urea
and creatinine were similar for all three filter membranes, and
the SCs of ceftazidime were not significantly different. No
significant differences in the clearances of urea and creatinine
were noted between filters at any level of nominal dialysate
inflow rate. The CVVHD clearance of total ceftazidime with
the PS filter was significantly higher at dialysate inflow rates of
25 and 33.3 ml/min than values with the AN69 filter (Table 2).
DISCUSSION
The disposition of ceftazidime (6, 12, 27) during CVVH has
been reported in single case reports or as a series of clinical
cases. Unfortunately, it is difficult, if not impossible, to control
the critical variables that may affect the clearance of ceftazidime in acutely ill patients. In this study, we prospectively
measured the SC and protein binding of ceftazidime in stable
ESRD patients undergoing controlled CVVH with three different hemofilters. The clearances of ceftazidime and two reference solutes (urea and creatinine) determined at two ultrafiltration flow rates confirmed the dependence of CVVH
clearance on QUF; the clearance of each solute increased significantly at the higher ultrafiltration rate (P ⫽ 0.0001). No
clinically significant difference in urea, creatinine, or ceftazidime clearance was attributed to the type of membrane utilized
for CVVH. The mean fup of ceftazidime in these patients was
similar to those in previous reports in normal volunteers (2)
and infected patients (9, 15). The mean measured fup of ceftazidime in these patients (n ⫽ 15) of 0.83 ⫾ 0.05 was very
consistent and did not significantly differ from the observed
mean SC of 0.91 ⫾ 0.17. These values are quite comparable to
the earlier report of an SC of 0.86 with an AN69 filter (27).
This confirms the dependence of ceftazidime CVVH clearance
on fup.
CVVHD allows independent regulation of blood, dialysate,
and ultrafiltrate flow rates, and clearance of solute during
CVVHD is comprised of both a diffusive component and a
convective (or ultrafiltration) component (23). Since net QUF
ranged from 3.0 to 9.2% of nominal QDI during the CVVHD
segment of this study, the observed ceftazidime clearances
predominantly reflect the effects of alterations in blood and

dialysate flow on diffusion across the membrane. Unfortunately, the previously published studies of ceftazidime clearance during CVVHD did not control ultrafiltration rate to this
degree, and thus their results cannot be directly compared to
our observations (6, 27). Furthermore, ceftazidime clearance
by CVVHD has been previously evaluated with only the AN69
filter. Thus, this study is the first rigorous investigation of the
determinants of ceftazidime clearance by CVVHD.
Increasing nominal dialysate inflow rate from 8.3 to 33.3
ml/min produced a linear increase in the clearance of urea and
creatinine with each of the three hemofilters. The slopes of the
urea clearance to QDI relationship with the AN69 filter during
the two segments of the study of ceftazidime (0.84) were similar to the values previously reported by Joy et al. (14) (0.77)
and Relton et al. (19) (0.88). Similar congruity in the urea
relationships was evident for the PS membrane; Ifediora et al.
(10) reported a slope of 0.85 for the Renal Systems HF-500
filter and 0.91 for the Fresenius F-8 filter, while Joy et al. (14)
observed a value of 0.80 with a Fresenius F-40 filter. These
data suggest that the choice among these three filter membranes is not a critical determinant of CVVHD performance
for control of azotemia (23).
The clearance of total and unbound ceftazidime increased
significantly as the nominal QDI was increased (Fig. 2). Total
ceftazidime clearance by the PS filter exceeded clearance by
the AN69 and PMMA filters at all dialysate inflow rates. However, the slopes of the relationship between total ceftazidime
clearance and urea clearance did not significantly differ between the three filters (Fig. 3). If diffusive clearance of ceftazidime by CVVHD were flow limited, then one would anticipate that increasing blood flow rate would result in an increase
in ceftazidime clearance. Within-filter comparisons revealed
that, when the dialysate inflow rate was constant, there was no
significant difference in urea or creatinine clearance as blood
flow rate was increased from 75 to 250 ml/min (P ⫽ 0.066).
However, at a blood flow rate of 250 ml/min, ceftazidime
clearance with the AN69 filter was significantly greater than
the value observed at the lowest blood flow rate (P ⫽ 0.031).
On the basis of these data, one can project that CVVH and
CVVHD therapy can significantly augment the clearance of
ceftazidime. The total body clearance of ceftazidime in patients with acute renal failure is comprised of residual renal
clearance and a nonrenal component. In patients with normal
renal function, the nonrenal clearance of ceftazidime is approximately 10.6 ml/min (18). The total body clearance of
ceftazidime for a patient with a residual creatinine clearance of
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FIG. 3. Relationship between ceftazidime clearance and urea clearance for the AN69 filter (clearance ⫽ 0.832 [urea clearance], r 2 ⫽ 0.956) (A), the filter
(clearance ⫽ 1.03 [urea clearance], r 2 ⫽ 0.951), (B) and the PMMA filter (clearance ⫽ 0.892 [urea clearance], r 2 ⫽ 0.933) (C).
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TABLE 3. CVVH dosage guidelines for ceftazidime
Maintenance dose (mg) for a ultrafiltration
rate (ml/min) of a:
5

16.7

33.3

50

0
5
10
15
20

250
250
250
250
500

250
250
500
500
500

500
500
500
500
500

500
500
750
750
750

a

Maintenance dose to be administered every 12 h.

10 ml/min would thus be 22.1 ml/min. The initiation of CVVH
with an ultrafiltration rate of 1.0 liter/h would thus result in an
increase of 60 to 73% in the total body clearance of ceftazidime. The contribution of CVVHD is even more dramatic and
dependent on the dialysate inflow rate employed and the patient’s residual renal function. One could anticipate a maximal
increase in the ceftazidime total body clearance of 121.7 to
146.6% for a patient with a residual creatinine clearance of 10
ml/min. In those patients with a higher degree of residual renal
function, the dosage regimen will need to be progressively
increased.
Maintenance dosage recommendations for patients receiving CVVH with any of the three filters evaluated in this study
after the initiation of ceftazidime therapy with a loading dose
of 1,000 mg are listed in Table 3. These regimens should result
in the maintenance of serum concentrations above the MIC90
of susceptible organisms for over 80% of the dosing interval.
Since some clinicians have proposed that the concentrations of
cephalosporins in serum only need to exceed the MIC90 for
40% of the dosage interval, once-a-day administration of the
doses in Tables 3 and 4 may be feasible (5). Furthermore, if
combination antibiotic therapy is initiated or subsequently
added, the desired clinical outcomes may be achieved with an
even lower percentage of time above MIC for the cephalosporin (22).
Projected ceftazidime dosage requirements for patients receiving CVVHD are listed in Table 4. Although combinations
of convective and diffusive transport may be beneficial in many
clinical settings, the impact of increasing convection on diffusive clearance was not explicitly evaluated. At the flow rates
clinically utilized, the clearances by the two processes are likely
to be additive (8). Thus, for CVVHD prescriptions, the urea
clearance during CVVHD could be measured and the dosage
adjustment of ceftazidime could be individualized on the basis
of the estimated ceftazidime clearance from the relationships

TABLE 4. Ceftazidime dosage guidelines during CVVHD
Maintenance dose (mg) for a dialysate inflow rate
of a:
Residual renal
function (creatinine
clearance in ml/min)

0
5
10
15
20
a

1.0 liter/h

2.0 liters/h

Ultrafiltration rate
(liter/h)

Ultrafiltration rate
(liters/h)

0.5

1.0

2.0

0.5

1.0

2.0

500
500
500
500
750

500
500
500
750
750

500
750
750
750
1,000

500
500
500
750
750

500
500
750
750
750

750
750
1,000
1,000
1,000

Maintenance dose to be administered every 12 h.

in Fig. 2 and 3, plus the patient’s residual renal and nonrenal
clearance as described previously.
In summary, these data indicate that the removal of ceftazidime by CVVH is dependent on the fup of the patient and
the delivered ultrafiltration rate. No filter membrane effect was
observed to be statistically or clinically significant for ceftazidime. Ceftazidime dosage regimens can be initiated on the
basis of the proposed dosing recommendations, and the contribution of CVVH or CVVHD clearance to the patient’s residual drug clearance can be subsequently utilized to individualize the antibiotic regimen on the basis of measured urea
clearances.
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